Although the role of ATG5 in CRC remains unclear due to the controversial results between in vitro and in vivo studies, it has been reported that the ATG5 locus was lost in more than 20% of CRC patients and that heterozygous or complete deletion of ATG5 led to increased cellular death and tumour burden and enhanced antitumor efficacy of IFN γ [43]. This evidence concerns the gene ATG5 and neoplasm.